Vaughan Nelson Investment Management L.P. cut its stake in The Cooper Companies, Inc. (NYSE:COO) by 5.2% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 76,790 shares of the medical device company’s stock after selling 4,205 shares during the period. Vaughan Nelson Investment Management L.P. owned about 0.14% of The Cooper Companies worth $25,889,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Whittier Trust Co. of Nevada Inc. purchased a new stake in The Cooper Companies in the third quarter valued at $28,000. Ellevest Inc. boosted its stake in shares of The Cooper Companies by 171.4% during the third quarter. Ellevest Inc. now owns 114 shares of the medical device company’s stock worth $38,000 after buying an additional 72 shares during the period. Simon Quick Advisors LLC acquired a new position in The Cooper Companies in the 3rd quarter valued at about $42,000. CX Institutional raised its stake in The Cooper Companies by 382.1% during the 3rd quarter. CX Institutional now owns 135 shares of the medical device company’s stock valued at $46,000 after acquiring an additional 107 shares during the last quarter. Finally, Braun Bostich & Associates Inc. acquired a new stake in The Cooper Companies during the 3rd quarter worth approximately $55,000. 88.84% of the stock is owned by hedge funds and other institutional investors.
COO has been the topic of several recent research reports. Stephens boosted their price objective on shares of The Cooper Companies from $325.00 to $365.00 and gave the company an “overweight” rating in a research note on Friday, September 4th. Oppenheimer reaffirmed a “hold” rating on shares of The Cooper Companies in a report on Thursday, September 24th. JPMorgan Chase & Co. raised their price target on The Cooper Companies from $285.00 to $315.00 and gave the company a “neutral” rating in a report on Friday, September 4th. Citigroup upped their price objective on The Cooper Companies from $310.00 to $330.00 and gave the stock a “neutral” rating in a report on Friday, September 4th. Finally, KeyCorp raised their target price on The Cooper Companies from $330.00 to $349.00 and gave the company an “overweight” rating in a report on Friday, September 4th. Five investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $338.77.
In other The Cooper Companies news, CEO Robert D. Auerbach sold 2,538 shares of the company’s stock in a transaction that occurred on Thursday, October 8th. The stock was sold at an average price of $350.00, for a total value of $888,300.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Gary S. Petersmeyer sold 1,000 shares of the stock in a transaction that occurred on Tuesday, October 6th. The shares were sold at an average price of $348.54, for a total transaction of $348,540.00. The disclosure for this sale can be found here. Insiders have sold a total of 10,038 shares of company stock worth $3,438,325 in the last 90 days. Company insiders own 1.40% of the company’s stock.
Shares of NYSE COO opened at $340.70 on Tuesday. The stock has a market capitalization of $18.17 billion, a PE ratio of 60.95, a P/E/G ratio of 2.66 and a beta of 0.87. The company has a quick ratio of 0.64, a current ratio of 1.17 and a debt-to-equity ratio of 0.35. The firm has a fifty day moving average of $342.42 and a 200-day moving average of $312.27. The Cooper Companies, Inc. has a 52-week low of $236.68 and a 52-week high of $371.59.
The Cooper Companies (NYSE:COO) last released its quarterly earnings data on Thursday, September 3rd. The medical device company reported $2.28 EPS for the quarter, topping analysts’ consensus estimates of $1.58 by $0.70. The company had revenue of $578.20 million for the quarter, compared to the consensus estimate of $536.11 million. The Cooper Companies had a return on equity of 13.19% and a net margin of 11.40%. The company’s quarterly revenue was down 14.9% compared to the same quarter last year. During the same period last year, the business posted $3.23 EPS. Equities research analysts expect that The Cooper Companies, Inc. will post 9.47 EPS for the current fiscal year.
The Cooper Companies Profile
The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.
Want to see what other hedge funds are holding COO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Cooper Companies, Inc. (NYSE:COO).
Receive News & Ratings for The Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.